GET DAILY SIGNALSEnvista Holdings (NVST) Delivers Q3 Earnings Beat and Raises Full-Year Guidance
Key Takeaways
- Envista Holdings reported third quarter 2026 sales of $691.5 million, up 3.2% year over year and essentially in line with Wall Street's consensus estimate of roughly $688 million.
- Adjusted earnings per share (EPS) came in at $0.40, beating the consensus estimate of $0.36 by about 12% and up from $0.32 in the prior-year quarter.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose to $106 million, reflecting a 15.3% adjusted EBITDA margin and an 8.9% beat versus consensus.
- Management raised its full-year 2026 adjusted EPS guidance to a range of $1.54 to $1.58, an increase from prior expectations.
- Reported GAAP (Generally Accepted Accounting Principles) results were significantly inflated by a one-time, non-cash currency translation gain, so investors should focus on adjusted figures.
- Free cash flow turned negative at roughly -$16 million, down from about $68 million in the same quarter a year ago.
Why These Results Matter
NVST operates as a global dental products company through its Specialty Products & Technologies and Equipment & Consumables segments. The third quarter 2026 results, released on November 4, 2026, provide a useful checkpoint on whether the company can sustain first-half momentum and turn modest top-line growth into stronger bottom-line performance.
After a solid start to the year, attention turned to margin expansion, competitive positioning in dental markets, and the ability to raise guidance again. The numbers also offer insight into demand trends for dental equipment and consumables, as well as progress under the Envista Business System continuous-improvement framework. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Quarter
For the fiscal third quarter ended October 2, 2026, NVST posted sales of $691.5 million, a 3.2% rise from $669.9 million a year earlier. Revenue came in close to the roughly $688 million consensus. Specialty Products & Technologies contributed $443.7 million (up 2.8%), while Equipment & Consumables added $247.8 million (up 3.9%).
Adjusted diluted EPS reached $0.40, ahead of the $0.36 estimate and above the $0.32 recorded last year. Adjusted net income climbed to $65.2 million from $53.7 million, and adjusted operating profit increased to $95.0 million from $85.6 million. Adjusted EBITDA hit about $106 million, producing a 15.3% margin that improved roughly 80 basis points year over year.
GAAP results included a large non-cash item. GAAP operating profit surged to $515.2 million from $57.5 million, and GAAP net income swung sharply higher, driven mainly by a roughly $428 million cumulative foreign currency translation gain from liquidating certain legal entities during a corporate simplification. This gain had no cash impact and left adjusted results unchanged.
Management lifted full-year 2026 adjusted EPS guidance to $1.54 to $1.58, with a midpoint of $1.56, reflecting continued confidence in margin expansion.
Market Reaction and Investor Views
The results were generally well received given the EPS beat and another guidance increase. The stock reaction stayed muted, however, with shares holding near the $27 level shortly after the release. Investors appeared to balance the positive margin and outlook signals against modest revenue growth of 3.2% and the shift to negative free cash flow. The one-time GAAP gain was largely discounted in favor of the adjusted metrics.
Forward Outlook and Points to Watch
The raised full-year adjusted EPS range of $1.54 to $1.58 underscores management’s view that margin initiatives can continue to deliver even in a slower-growth revenue environment. Further operating leverage may come from ongoing efficiency gains under the Envista Business System.
Cash generation stands out as an area to monitor. Free cash flow turned negative at roughly -$16 million versus a positive $67.9 million a year earlier, creating a contrast with the improving profitability picture. Investors will want to determine whether this reflects a temporary working-capital shift or something more persistent.
Dental procedure volumes and equipment demand will also remain key. With analysts expecting only modest single-digit revenue growth over the next twelve months, the pace of industry spending will influence whether NVST can keep exceeding profit expectations. Currency moves and any additional corporate-structure steps could add more one-time items, so sticking with adjusted figures will stay important for assessing underlying performance.
Using Tickeron’s AI Tools in My Research
I often turn to Tickeron’s AI Screener when reviewing earnings like these. It helps me quickly filter stocks by technical patterns, fundamentals, and sector trends, giving a clearer picture of how names in the dental and healthcare space stack up. This kind of AI-driven screening supports more efficient idea generation without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NVST in upward trend: price rose above 50-day moving average on November 02, 2026
NVST moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NVST as a result. In 69 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for NVST just turned positive on October 06, 2026. Looking at past instances where NVST's MACD turned positive, the stock continued to rise in 32 of 49 cases over the following month. The odds of a continued upward trend are 65%.
Following a +10.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVST advanced for three days, in 171 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for NVST moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
NVST broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NVST entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. NVST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.420) is normal, around the industry mean (5.069). P/E Ratio (46.085) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.451) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of dental products for diagnosing, treating and preventing dental conditions
Industry PharmaceuticalsOther
Advertisement